Oncologie

, Volume 10, Issue 7–8, pp 463–465 | Cite as

Cancers gynécologiques

Compte Rendu / Conference Report
  • 31 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Domingo E, Lorvidhaya V, De Los Reyes R, et al. (2008) Capecitabine and radiotherapy in locally advanced squamous carcinoma of the uterine cervix: phase II results. J Clin Oncol 15S, Abstract 5513Google Scholar
  2. 2.
    Ferreira CG, Erlich F, Carmo CC, et al. (2008) Erlotinib combined with cisplatin and radiotherapy for patients with locally advanced squamous cell cervical cancer: a phase II trial. J Clin Oncol 15S, Abstract 5511Google Scholar
  3. 3.
    Gordon AN, Teneriello MG, Spirtos N, et al. (2008) Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by elective paclitaxel consolidation in advanced ovarian cancer: interim analysis of induction chemotherapy. J Clin Oncol 15S, Abstract 5536Google Scholar
  4. 4.
    Haie-Meder C, de Crevoisier R, Bruna A, et al. (2005) Concomitant chemoradiation in patients with cervix cancer. Bull Cancer 92: 1032–1038PubMedGoogle Scholar
  5. 5.
    Hoskins PJ, Vergote I, Stuart G, et al. (2008) A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin + paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV 16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC, GCG, and GEICO. J Clin Oncol 15S, Abstract LBA5505Google Scholar
  6. 6.
    Isonishi S, Yasuda M, Takahashi F, et al. (2008) Randomized phase III trial of conventional paclitaxel and carboplatin versus dose dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 15S, Abstract 5506Google Scholar
  7. 7.
    Kaye SB, Poole CJ, Bidzinski M, et al. (2008) A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J Clin Oncol 15S, Abstract 5520Google Scholar
  8. 8.
    Kristensen G, Kaern J, Baekelandt M, et al. (2008) Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study. J Clin Oncol 15S, Abstract 5508Google Scholar
  9. 9.
    Lalla D, Paton V, Lin CY, et al. (2008) Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum-resistant disease. J Clin Oncol 15S, Abstract 5550Google Scholar
  10. 10.
    Long HJ 3rd, Bundy BN, Grendys EC Jr., et al. (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23: 4626–4633PubMedCrossRefGoogle Scholar
  11. 11.
    Monk BJ, Sill M, McMeekin DS, et al. (2008) A randomized phase III trial of four cisplatin containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 15S, Abstract LBA5504Google Scholar
  12. 12.
    Nout RA, Putter H, Jürgenliemk-Schultz IM, et al. (2008) Vaginal brachytherapy versus external beam pelvic radiotherapy for highintermediate risk endometrial cancer. Results of the randomized PORTEC II trial. J Clin Oncol 15S, Abstract LBA5503Google Scholar
  13. 13.
    Oza AM, Elit D, Provencher D, et al. (2008) A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 15S, Abstract 5516Google Scholar
  14. 14.
    Scholten AN, van Putten WL, Beerman H, et al. (2005) Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63: 834–838PubMedGoogle Scholar
  15. 15.
    Seidman AD, Berry D, Cirrincione C, et al. (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 6: 1642–1649CrossRefGoogle Scholar
  16. 16.
    Slomovitz BM, Lu KH, Johnston T, et al. (2008) A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma. J Clin Oncol 15S, Abstract 5502Google Scholar
  17. 17.
    Sparano JA, Wang M, Martino S, et al. (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: 1663–1671PubMedCrossRefGoogle Scholar
  18. 18.
    Wenzel LB, Huang H, Cella D, et al. (2008) Quality-of-life results of a randomized phase III trial of four cisplatin containing doublet combinations in stage IVB cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 15S, Abstract 5529Google Scholar

Copyright information

© Springer Verlag France 2008

Authors and Affiliations

  1. 1.Département d’oncologie médicaleCLCC Paul-StraussStrasbourg cedexFrance

Personalised recommendations